Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Slides:

Advertisements

Similar presentations

Usman Ahmad, MD, Zuoheng Wang, PhD, Ayesha S

Advertisements

Elizabeth A. David, MD, David T

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Thomas J. Birdas, MD, Richard P. M

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database Traves D. Crabtree,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.

Ravi Rajaram, MD, MSc, Jennifer L

A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective.

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy

Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery

Non-Small Cell Lung Cancer Resection in Lymphoma Patients

Second Primary Lung Cancers: Smokers Versus Nonsmokers After Resection of Stage I Lung Adenocarcinoma R. Taylor Ripley, MD, Robert R. McMillan, MD, MPH,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Prognostic Predictors in Non-Small Cell Lung Cancer Patients Undergoing Intentional Segmentectomy Terumoto Koike, MD, PhD, Teruaki Koike, MD, PhD, Yasushi.

Adding Radiotherapy to Adjuvant Chemotherapy Does Not Improve Survival of Patients With N2 Lung Cancer Justin A. Drake, MD, David C. Portnoy, MD, Kurt.

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer Aalok P. Patel, BS, Traves D. Crabtree,

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Community-Based Multidisciplinary Computed Tomography Screening Program Improves Lung Cancer Survival Daniel L. Miller, MD, William R. Mayfield, MD,

Felix G. Fernandez, MD, Chadrick E. Denlinger, MD, G

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Thomas J. Birdas, MD, Richard P. M

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

Andrea S. Wolf, MD, William G. Richards, PhD, Michael T

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis Pamela Samson, MD, Aalok Patel, BS,

Tara R. Semenkovich, MD, MPHS, Christine Frederiksen, MS, Jessica L

Kevin L. Anderson, MHSc, Michael S. Mulvihill, MD, Paul J

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

Survival After Lobectomy Versus Segmentectomy for Stage I Non-Small Cell Lung Cancer: A Population-Based Analysis Bryan A. Whitson, MD, PhD, Shawn S.

Use of Amiodarone After Major Lung Resection

Impact of Video-Assisted Thoracoscopic Surgery on Benign Resections for Solitary Pulmonary Nodules Elbert Kuo, MD, MPH, Ankit Bharat, MD, Nicholas Bontumasi,

Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Non–Small Cell Lung Cancer Raymond U.

Treatment Outcomes in Stage I Lung Cancer

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? Samuel Kim, MD, David A. Bull, MD, Linda Garland, MD,

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Predictors of Long-Term Survival After Resection of Esophageal Carcinoma With Nonregional Nodal Metastases Paul C. Lee, MD, Jeffrey L. Port, MD, Subroto.

Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy Pamela Samson, MD, MPHS,

Mara B. Antonoff, MD, Varun Puri, MD, Bryan F

Jonathan D. Spicer, MD, PhD, Jitesh B. Shewale, BDS, PhD, David B

Office-Based Spirometry: A New Model of Care in Preoperative Assessment for Low- Risk Lung Resections Jessica L. Hudson, MD, MPHS, Jennifer M. Bell, BSN,

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Mara B. Antonoff, MD, Wayne L. Hofstetter, MD, Arlene M

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Matthew J. Schuchert, MD, Omar Awais, DO, Ghulam Abbas, MD, Zachary D

Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? Bryan F. Meyers,

Varun Puri, MD, Yinin Hu, MS, Tracey Guthrie, RN, Traves D

Yinin Hu, MD, Timothy L. McMurry, PhD, Kristen M. Wells, PhD, James M

Treatment of Malignant Pleural Effusion: A Cost-Effectiveness Analysis

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Lobectomy Versus Limited Resection in T1N0 Lung Cancer

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Presentation transcript:

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree, MD, Aalok P. Patel, BS, Daniel Morgensztern, MD, Cliff G. Robinson, MD, A. Sasha Krupnick, MD, Daniel Kreisel, MD, PhD, David R. Jones, MD, G. Alexander Patterson, MD, Bryan F. Meyers, MD, MPH, Varun Puri, MD, MSCI The Annals of Thoracic Surgery Volume 104, Issue 1, Pages 303-307 (July 2017) DOI: 10.1016/j.athoracsur.2017.01.069 Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 Overall survival (OS) in patients with non-small cell lung cancer (NSCLC) who underwent lobectomy with chest wall resection with or without adjuvant chemotherapy (chemo). N = 824, no chemo = 569, adjuvant chemo = 255. Median OS 19 versus 36 months, p < 0.001. (Cum = cumulative; Dx = diagnosis.) The Annals of Thoracic Surgery 2017 104, 303-307DOI: (10.1016/j.athoracsur.2017.01.069) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Overall survival (OS) in patients with non-small cell lung cancer (NSCLC) who underwent lobectomy with chest wall resection with complete or incomplete resection. N = 806, complete resection = 705, incomplete resection = 101. Median OS 27 versus 13 months, p < 0.001. (Cum = cumulative; Dx = diagnosis.) The Annals of Thoracic Surgery 2017 104, 303-307DOI: (10.1016/j.athoracsur.2017.01.069) Copyright © 2017 The Society of Thoracic Surgeons Terms and Conditions